Clinical trial · no report yet · Phase 2

LOTIS-9

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)

NCT05144009 ↗
Terminated
ADC Therapeutics S.A.
Focused

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

Channel	Found
X threads	4
Podcasts	1

The trial

ClinicalTrials.gov

Official title: A Phase 2 Open-label Study of Loncastuximab Tesirine in Combination With Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)
Phase: Phase 2
Status: Terminated
Conditions: Diffuse Large B-cell Lymphoma
Interventions: Loncastuximab Tesirine; Rituximab
Arms: Cohort A : Loncastuximab Tesirine + Rituximab (Lonca-R) · Experimental
Cohort B : Loncastuximab Tesirine + Rituximab (Lonca-R) · Experimental
Enrollment: 41
Primary outcomes: CR Rate
Cohort B: Percentage of Participants Who Completed 4 Cycles of Treatment
Sponsor: ADC Therapeutics S.A.
Start: Jun 21, 2022
Primary completion: Jan 22, 2024
Results posted: Yes
Registry record: NCT05144009 · updated Jan 30, 2025

Publications

linked from the registry

Nair R, Kumar A, Chapman AE, Levy MY, Sharman JP, Choudhary Y, Jehangir W, Melear JM, Urban A, Niewarowski A, Wang L, Toukam M, Burke JM, Westin JR. Loncastuximab and Rituximab in Elderly Unfit/Frail Patients With Previously Untreated Diffuse Large B-Cell Lymphoma. Blood Adv. 2026 Oct 15:bloodadvances.2026020494. doi: 10.1182/bloodadvances.2026020494. Online ahead of print. PubMed 42879743